Ex vivo modifiable medicament release-associations

• US 20100068278A1
• Filed: 04/29/2009
• Published: 03/18/2010
• Est. Priority Date: 09/16/2008
• Status: Abandoned Application

• Current Assignee: Searete LLC (Intellectual Ventures LLC)
• Original Assignee: Searete LLC A Limited Liability Corporation of The State of Delaware
• Inventors: Ishikawa, Muriel Y., Boyden, Edward S., Wood, Lowell L. JR., Rivet, Dennis J., Hyde, Roderick A., Sweeney, Elizabeth A., Wood, Victoria Y.H., Bangera, Mahalaxmi Gita
• Application Number:
  US12/387,328
• Publication Number:
  US 20100068278A1
• Time in Patent Office: Days
• US Class Current: 424/484
• CPC Class Codes: A61K 9/06 Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels composition of ointments, creams or gels A61K47/00
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61K 9/4891 Coated capsules; Multilayered drug free capsule shells with drug coating for immediate release A61K9/4808; osmotic devices A61K9/0004
• CPC Class Codes: A61K 9/51 Nanocapsules; Nanoparticles; nanotubes A61K9/0092; polymeric micelles A61K9/1075; polymersomes A61K9/1273; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K47/50; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: G16H 20/10 relating to drugs or medications, e.g. for ensuring correct administration to patients

Abstract

Described embodiments include a final dosage form, an article of manufacture, and method. A described final dosage form includes a medicament, and a substance associated with the medicament in a first release-control state. In the first release-control state, the medicament has a first bioavailability to the animal. The substance is modifiable ex vivo by an exposure to a stimulus to associate with the medicament in a second release-control state, wherein the medicament has a second bioavailability to the animal. The final dosage form also includes another medicament, and another substance associated with the another medicament in another first release-control state. In the another first release-control state, the another medicament has another first bioavailability to the animal. The another substance is modifiable ex vivo by an exposure to another stimulus to associate with the another medicament in another second release-control state, wherein the another medicament has another second bioavailability.

Claims

1. A final dosage form for administering medicament to an animal, the final dosage form including

a medicament;

a substance associated with the medicament in a first release-control state, wherein the medicament has a first bioavailability to the animal if the final dosage form is administered to the animal,

the substance modifiable ex vivo by an exposure to a stimulus to associate with the medicament in a second release-control state, wherein the medicament has a second bioavailability to the animal if the final dosage form is administered to the animal;

another medicament; and

another substance associated with the another medicament in another first release-control state, wherein the another medicament has another first bioavailability to the animal if the final dosage form is administered to the animal,

the another substance modifiable ex vivo by an exposure to another stimulus to associate with the another medicament in another second release-control state, wherein the another medicament has another second bioavailability to the animal if the final dosage form is administered to the animal.

2. The final dosage form of claim 1, wherein the substance associated with the medicament in a first release-control state includes:

a particle associated with the medicament in a first release-control state.

3. The final dosage form of claim 1, wherein the substance associated with the medicament in a first release-control state includes:

a polymeric material associated with the medicament in a first release-control state.

4. The final dosage form of claim 1, wherein the substance associated with the medicament in a first release-control state includes:

a small molecule associated with the medicament in a first release-control state.

5. The final dosage form of claim 1, wherein the substance associated with the medicament in a first release-control state includes:

an intelligent molecule associated with the medicament in a first release-control state.

6. The final dosage form of claim 1, wherein the substance associated with the medicament in a first release-control state includes:

an encapsulating substance associated with the medicament in a first release-control state.

7. The final dosage form of claim 1, wherein the substance associated with the medicament in a first release-control state includes:

a conjugating substance joined with the medicament in a first release-control state.

8. The final dosage form of claim 1, wherein the substance associated with the medicament in a first release-control state includes:

a binding substance bound with the medicament in a first release-control state.

9. The final dosage form of claim 1, wherein the substance associated with the medicament in a first release-control state includes:

a substance at least one of engaging, or retaining the medicament in a first release-control state.

10. The final dosage form of claim 1, wherein the first bioavailability includes a first bioavailability characteristic and the second bioavailability includes a second bioavailability characteristic.

11. The final dosage form of claim 1, wherein the first bioavailability to the animal includes the medicament being substantially not bioavailable to the animal.

12. The final dosage form of claim 1, wherein the first bioavailability to the animal includes the medicament being substantially bioavailable to the animal.

13. The final dosage form of claim 1, wherein the second bioavailability to the animal includes the medicament being substantially not bioavailable to the animal.

14. The final dosage form of claim 1, wherein the second bioavailability to the animal includes the medicament being substantially bioavailable to the animal.

15. The final dosage form of claim 1, wherein the second bioavailability to the animal includes the medicament being substantially bioavailable to the animal, wherein the second bioavailability to the animal is substantially different than the first bioavailability to the animal.

16. A final dosage form for administering medicament to an animal, the final dosage form comprising:

a medicament;

a substance associated with the medicament in a first state, wherein the medicament has a first bioavailability to the animal if the final dosage form is administered to the animal,

the substance modifiable ex vivo by an exposure to a stimulus to associate with the medicament in a second state, wherein the medicament has a second bioavailability to the animal if the final dosage form is administered to the animal;

another medicament; and

another substance associated with the another medicament in another first state, wherein the another medicament has another first bioavailability to the animal if the final dosage form is administered to the animal,

the another substance modifiable ex vivo by an exposure to another stimulus to associate with the another medicament in another second state, wherein the another medicament has another second bioavailability to the animal if the final dosage form is administered to the animal.

17. A method of modifying bioavailability of medicament provided by a final dosage form for administering medicament to an animal, wherein the final dosage form includes

a medicament;

a substance associated with the medicament in a first release-control state, wherein the medicament has a first bioavailability to the animal if the final dosage form is administered to the animal,

the substance modifiable ex vivo by an exposure to a stimulus to associate with the medicament in a second release-control state, wherein the medicament has a second bioavailability to the animal if the final dosage form is administered to the animal;

another medicament; and

another substance associated with the another medicament in another first release-control state, wherein the another medicament has another first bioavailability to the animal if the final dosage form is administered to the animal,

the another substance modifiable ex vivo by an exposure to another stimulus to associate with the another medicament in another second release-control state, wherein the another medicament has another second bioavailability to the animal if the final dosage form is administered to the animal;

the method comprising;

transforming the final dosage form into a selected medicament release state by initiating an ex vivo exposure of the substance associated with the medicament in a first release-control state or an ex vivo exposure of the another substance associated with the another medicament in another first release-control state to a modification stimulus respectfully selected from the stimulus or the another stimulus.

18. The method of claim 17, wherein the transforming the final dosage form into a selected medicament release state by initiating an ex vivo exposure of the substance associated with the medicament in a first release-control state or an ex vivo exposure of the another substance associated with the another medicament in another first release-control state to a modification stimulus respectfully selected from the stimulus or the another stimulus includes:

transforming the final dosage form into a selected medicament release state by initiating an ex vivo exposure of the substance associated with the medicament in a first release-control state and an ex vivo exposure of the another substance associated with the another medicament in another first release-control state to the stimulus and the another stimulus.

19. The method of claim 17, further comprising:

receiving a signal indicative of a chosen medicament bioavailability of the final dosage form.

20. The method of claim 19, wherein receiving a signal indicative of a chosen medicament bioavailability of the final dosage form includes:

receiving a machine-initiated signal indicative of a chosen medicament bioavailability of the final dosage form.

21. The method of claim 19, wherein receiving a signal indicative of a chosen medicament bioavailability of the final dosage form includes:

receiving a human-initiated signal indicative of a chosen medicament bioavailability of the final dosage form.

22. The method of claim 17, further comprising:

selecting the medicament-release state of the substance associated with the medicament or of the another substance associated with the another medicament in response to the chosen medicament-bioavailability of the final dosage form.

23. The method of claim 22, wherein the selecting the medicament-release state of the substance associated with the medicament or of the another substance associated with the another medicament in response to the chosen medicament-bioavailability of the final dosage form includes:

electronically selecting the medicament-release state of the substance associated with the medicament or of the another substance associated with the another medicament in response to the chosen medicament-bioavailability of the final dosage form, the selecting a medicament-release state based on an electronically-stored database relating medicament-release state and medicament-bioavailability of the final dosage form, a computer-implemented decision table, a digitally-maintained final dosage form transformation table, or a digital library correlating medicament-release state and medicament-bioavailability of the final dosage form.

24. The method of claim 17, further comprising:

selecting the modification stimulus from the stimulus or the another stimulus in response to the selected medicament-release state.

25. The method of claim 24, wherein the selecting the modification stimulus from the stimulus or the another stimulus in response to the selected medicament-release state includes:

electronically selecting the modification stimulus from the stimulus or the another stimulus in response to the selected medicament-release state, the selecting the modification stimulus based on an electronically-stored database relating stimuli and medicament-release state of the final dosage form, a computer-implemented decision table, a digitally-maintained final dosage form transformation table, or a digital library correlating medicament-release state of the final dosage form and stimuli.

26. An article of manufacture for administering medicament to an animal, the article comprising:

a medicament;

an intelligent molecular means associated with the medicament in a first release-control state, wherein the medicament has a first bioavailability to the animal if the article of manufacture is administered to the animal,

the intelligent molecular means modifiable ex vivo by an exposure to a stimulus to associate with the medicament in a second release-control state, wherein the medicament has a second bioavailability to the animal if the article of manufacture is administered to the animal;

another medicament; and

another intelligent molecular means associated with the another medicament in another first release-control state, wherein the another medicament has another first bioavailability to the animal if the article of manufacture is administered to the animal,

the another intelligent molecular means modifiable ex vivo by an exposure to another stimulus to associate with the another medicament in another second release-control state, wherein the another medicament has another second bioavailability to the animal if the article of manufacture is administered to the animal.